A proteomic approach for the identification of biomarkers in endometrial cancer uterine aspirate

Blendi Ura, Lorenzo Monasta, Giorgio Arrigoni, Cinzia Franchin, Oriano Radillo, Isabel Peterlunger, Giuseppe Ricci, Federica Scrimin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Endometrial cancer arises from the endometrium. It has a slow progression and a reported survival rate of 75%. The identification of soluble biomarkers in the uterine aspirate may be very useful for its early diagnosis. Uterine aspirates from 10 patients with endometrial cancer and 6 non-endometrial cancer controls were analyzed by two-dimensional gel electrophoresis coupled with mass spectrometry and western blotting for data verification. A total of 25 proteins with fold change in %V ≥2 or ≤0.5 in intensity were observed to change significantly (P < 0.05). From the discovery phase, four proteins (costars family protein ABRACL, phosphoglycerate mutase 2, fibrinogen beta chain, annexin A3) were found to be present in the uterine aspirate of endometrial cancers and not in healthy aspirates. Western blotting verification data demonstrated that costars family protein ABRACL, phosphoglycerate mutase 2 were present only in endometrial cancer uterine aspirate while fibrinogen beta chain, annexin A3 were also present in healthy aspirates. To our knowledge, phosphoglycerate mutase 2 has not been previously associated with endometrial cancer. In this study we demonstrate that uterine aspirates are a promising biological fluid in which to identify endometrial cancer biomarkers. In our opinion proteins like costars family protein ABRACL and phosphoglycerate mutase 2 have a great potential to reach the clinical phase after a validation phase.

Original languageEnglish
Pages (from-to)109536-109545
Number of pages10
JournalOncotarget
Volume8
Issue number65
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Endometrial Neoplasms
Proteomics
Phosphoglycerate Mutase
Biomarkers
Annexin A3
Proteins
Fibrinogen
Western Blotting
Electrophoresis, Gel, Two-Dimensional
Tumor Biomarkers
Early Diagnosis
Mass Spectrometry
Survival Rate
Neoplasms

Keywords

  • Biomarkers
  • Endometrial neoplasms
  • Mass spectrometry
  • Two dimensional electrophoresis
  • Uterine aspirate

ASJC Scopus subject areas

  • Oncology

Cite this

A proteomic approach for the identification of biomarkers in endometrial cancer uterine aspirate. / Ura, Blendi; Monasta, Lorenzo; Arrigoni, Giorgio; Franchin, Cinzia; Radillo, Oriano; Peterlunger, Isabel; Ricci, Giuseppe; Scrimin, Federica.

In: Oncotarget, Vol. 8, No. 65, 01.01.2017, p. 109536-109545.

Research output: Contribution to journalArticle

@article{39c15064e2dc443a84e4576b08c886f8,
title = "A proteomic approach for the identification of biomarkers in endometrial cancer uterine aspirate",
abstract = "Endometrial cancer arises from the endometrium. It has a slow progression and a reported survival rate of 75{\%}. The identification of soluble biomarkers in the uterine aspirate may be very useful for its early diagnosis. Uterine aspirates from 10 patients with endometrial cancer and 6 non-endometrial cancer controls were analyzed by two-dimensional gel electrophoresis coupled with mass spectrometry and western blotting for data verification. A total of 25 proteins with fold change in {\%}V ≥2 or ≤0.5 in intensity were observed to change significantly (P < 0.05). From the discovery phase, four proteins (costars family protein ABRACL, phosphoglycerate mutase 2, fibrinogen beta chain, annexin A3) were found to be present in the uterine aspirate of endometrial cancers and not in healthy aspirates. Western blotting verification data demonstrated that costars family protein ABRACL, phosphoglycerate mutase 2 were present only in endometrial cancer uterine aspirate while fibrinogen beta chain, annexin A3 were also present in healthy aspirates. To our knowledge, phosphoglycerate mutase 2 has not been previously associated with endometrial cancer. In this study we demonstrate that uterine aspirates are a promising biological fluid in which to identify endometrial cancer biomarkers. In our opinion proteins like costars family protein ABRACL and phosphoglycerate mutase 2 have a great potential to reach the clinical phase after a validation phase.",
keywords = "Biomarkers, Endometrial neoplasms, Mass spectrometry, Two dimensional electrophoresis, Uterine aspirate",
author = "Blendi Ura and Lorenzo Monasta and Giorgio Arrigoni and Cinzia Franchin and Oriano Radillo and Isabel Peterlunger and Giuseppe Ricci and Federica Scrimin",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.22725",
language = "English",
volume = "8",
pages = "109536--109545",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "65",

}

TY - JOUR

T1 - A proteomic approach for the identification of biomarkers in endometrial cancer uterine aspirate

AU - Ura, Blendi

AU - Monasta, Lorenzo

AU - Arrigoni, Giorgio

AU - Franchin, Cinzia

AU - Radillo, Oriano

AU - Peterlunger, Isabel

AU - Ricci, Giuseppe

AU - Scrimin, Federica

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Endometrial cancer arises from the endometrium. It has a slow progression and a reported survival rate of 75%. The identification of soluble biomarkers in the uterine aspirate may be very useful for its early diagnosis. Uterine aspirates from 10 patients with endometrial cancer and 6 non-endometrial cancer controls were analyzed by two-dimensional gel electrophoresis coupled with mass spectrometry and western blotting for data verification. A total of 25 proteins with fold change in %V ≥2 or ≤0.5 in intensity were observed to change significantly (P < 0.05). From the discovery phase, four proteins (costars family protein ABRACL, phosphoglycerate mutase 2, fibrinogen beta chain, annexin A3) were found to be present in the uterine aspirate of endometrial cancers and not in healthy aspirates. Western blotting verification data demonstrated that costars family protein ABRACL, phosphoglycerate mutase 2 were present only in endometrial cancer uterine aspirate while fibrinogen beta chain, annexin A3 were also present in healthy aspirates. To our knowledge, phosphoglycerate mutase 2 has not been previously associated with endometrial cancer. In this study we demonstrate that uterine aspirates are a promising biological fluid in which to identify endometrial cancer biomarkers. In our opinion proteins like costars family protein ABRACL and phosphoglycerate mutase 2 have a great potential to reach the clinical phase after a validation phase.

AB - Endometrial cancer arises from the endometrium. It has a slow progression and a reported survival rate of 75%. The identification of soluble biomarkers in the uterine aspirate may be very useful for its early diagnosis. Uterine aspirates from 10 patients with endometrial cancer and 6 non-endometrial cancer controls were analyzed by two-dimensional gel electrophoresis coupled with mass spectrometry and western blotting for data verification. A total of 25 proteins with fold change in %V ≥2 or ≤0.5 in intensity were observed to change significantly (P < 0.05). From the discovery phase, four proteins (costars family protein ABRACL, phosphoglycerate mutase 2, fibrinogen beta chain, annexin A3) were found to be present in the uterine aspirate of endometrial cancers and not in healthy aspirates. Western blotting verification data demonstrated that costars family protein ABRACL, phosphoglycerate mutase 2 were present only in endometrial cancer uterine aspirate while fibrinogen beta chain, annexin A3 were also present in healthy aspirates. To our knowledge, phosphoglycerate mutase 2 has not been previously associated with endometrial cancer. In this study we demonstrate that uterine aspirates are a promising biological fluid in which to identify endometrial cancer biomarkers. In our opinion proteins like costars family protein ABRACL and phosphoglycerate mutase 2 have a great potential to reach the clinical phase after a validation phase.

KW - Biomarkers

KW - Endometrial neoplasms

KW - Mass spectrometry

KW - Two dimensional electrophoresis

KW - Uterine aspirate

UR - http://www.scopus.com/inward/record.url?scp=85037675655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037675655&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.22725

DO - 10.18632/oncotarget.22725

M3 - Article

AN - SCOPUS:85037675655

VL - 8

SP - 109536

EP - 109545

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 65

ER -